Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06991257 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
A Phase 2 study of Heart Failure, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 620
- Enrollment target
- 20
- Study locations
NCT06991257 is a Phase 2 study of Heart Failure that is actively recruiting participants, run by Pfizer. The registered enrollment target is 620 participants, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT06991257, a Phase 2 study of Heart Failure, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 620 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Low Dose PF-07328948
- DRUG Medium Dose PF-07328948
- DRUG High Dose PF-07328948
Study Locations (20)
Illinois
- NMH Clinical Research Unit - Chicago
- Northwestern Memorial HealthCare - Arkes Pavilion - Chicago
- Northwestern Memorial HealthCare - Feinberg Pavilion - Chicago
- Northwestern Memorial HealthCare - Galter Pavilion - Chicago
- Northwestern Memorial Hospital Investigational Drug Service (IDS) - Chicago
- Northwestern University - Evanston
- Chicago Medical Research - Hazel Crest
Florida
- FWD Clinical Research - Boca Raton
- Jacksonville Center for Clinical Research - Jacksonville
- Infinite Clinical Research - Miami
- Flourish Research Acquisition, LLC dba Flourish Research - North Miami - Miami
- Amavita Research Services - North Miami Beach
- Clinical Site Partners, LLC dba Flourish Research - Winter Park
California
- National Heart Institute - Beverly Hills
- Orange County Research Center - Lake Forest
- Comprehensive Cardiovascular Care - Santa Maria
- FOMAT Medical Research - Santa Maria
Indiana
- NexGen Research - Fort Wayne
- Reid Physician Associates - Richmond
Maryland
- Ascension Saint Agnes Heart Care - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2025-06-19 |
| Est. Completion | 2027-12-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06991257
The ClinicalTrials.gov registry entry for NCT06991257 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 620 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,047-participant average among 397 other Heart Failure trials with a reported enrollment target (70% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT06991257 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Florida, California.
Frequently Asked Questions
What is clinical trial NCT06991257 about?
NCT06991257 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)". The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).
What is the current status of trial NCT06991257?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 620 participants. The study started on 2025-06-19. Estimated completion is 2027-12-14.
What conditions does trial NCT06991257 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT06991257?
The interventions under investigation include: Placebo (DRUG), Low Dose PF-07328948 (DRUG), Medium Dose PF-07328948 (DRUG), High Dose PF-07328948 (DRUG).
Who is sponsoring clinical trial NCT06991257?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06991257 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
RECRUITING · Phase 2
-
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 2
-
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
-
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RECRUITING · Phase 2
-
Ertugliflozin in Chronic Heart Failure
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.